Gastrointestinal Cancers

Patients with advanced gastric cancer received PD-1 inhibitors at similar rates across racial groups, although overall use remained limited in real-world care.

Providing patient-centered education and navigation support significantly increases consent rates for genomic testing, making testing integration feasible.

Nutritional support helps malnourished patients with advanced gastric cancer maintain chemotherapy and may extend time to treatment failure.

Updated data from GOBLET Cohort 4 demonstrated activity with Reolysin plus Tecentriq in patients with third-line metastatic squamous cell anal carcinoma.

Understanding your diagnosis, the tests ahead and the treatment landscape is the first step in regaining a sense of control.

ECOG performance status was found to capture only part of the patient experience in gastric/GEJ adenocarcinoma.

These were the top gastrointestinal cancer stories published by CURE in 2025.

Education is a vital step in navigating gallbladder cancer care.

An expert discusses how precision oncology, immunotherapy, biomarker testing and clinical trials are expanding treatment options for patients with gastric cancer.

I share how an overlooked symptom led to my anal cancer diagnosis and why speaking openly about risks, stigma and symptoms can help others seek care sooner.

A diagnosis of anal cancer can feel overwhelming, but understanding the disease is the first step toward effective management and recovery.

Cindy and Katie share how finding a friend who understood the caregiving journey made the experience less isolating and helped them navigate loss and hope.

The oral therapy DPTX3186 received fast track status to help speed development of a potential new option for patients with gastric cancer.

These are the basics of bile duct cancer, from diagnosis to treatment.

Long-awaited progress in rectal and gastric cancer research includes a fast track designation and new survival data.

Dr. Vinayak Venkataraman recently sat down with CURE to discuss the evolving treatment landscape for gastrointestinal stromal tumors.

The U.S. FDA has granted orphan drug designation to DPTX3186, an investigational therapy being developed for gastric cancer treatment.

Among patients with gastric/gastroesophageal junction (G/GEJ) adenocarcinoma that is resectable, Imfinzi with FLOT improved survival.

The FDA granted fast track designation to NG-350A for the treatment of patients with mismatch repair-proficient locally advanced rectal cancer.

After a stage 3b rectal cancer diagnosis, one patient endured radiation, chemotherapy, surgery, and complications, relying on resilience, advocacy and support.

Genetic testing before chemotherapy may help improve safety and guide treatment for patients with gastrointestinal cancers.

Here is a primer on what patients who have received a diagnosis of gastrointestinal cancer need to know.

Imfinzi plus chemo cut progression or death risk in early gastric cancer; the FDA's decision is expected late 2025 following breakthrough designation.

Zanzalintinib plus Tecentriq significantly improved overall survival versus Stivarga in previously treated metastatic colorectal cancer, phase 3 data show.

New or persistent acid reflux, especially after age 50, may mean higher risk for esophageal cancer, particularly in people with other known risk factors.